Finanzen von CervoMed Inc (CRVO)CRVOCervoMed Inc

CervoMed Inc (CRVO) generates its revenue primarily from ProElite, which accounts for 100.0% of total sales, equivalent to $72.00K. Understanding this concentration is critical for investors evaluating how CRVO navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, CervoMed Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -107.62%, provide a clear picture of how effectively CRVO converts its operational activities into shareholder value.

In the context of the broader market, CRVO competes directly with industry leaders such as CELU and TC. With a market capitalization of $21.32M, it holds a significant position in the sector. When comparing efficiency, CRVO's gross margin of N/A stands against CELU's 56.79% and TC's 6.39%. Such benchmarking helps identify whether CervoMed Inc is trading at a premium or discount relative to its financial performance.

CervoMed has reported significant financial losses, with a net income of -$7,964,158 for Q1 2026 and a consistent decline in revenue, culminating in a total revenue of only $3,225,693 for the last four quarters combined. The gross margin remains high at 100% but is not translating into profitability due to high operational costs.